
    
      This is a Phase 1, open-label, sequential, multiple-dose, drug-drug interaction study of GK
      activator HMS5552 and metformin in patients with type 2 diabetes mellitus (T2DM). The study
      is to assess the potential pharmacokinetic interaction between HMS5552 and metformin in
      subjects with T2DM. The study is also to evaluate the safety and tolerability of HMS5552 with
      simultaneous administration of metformin in subjects with T2DM.
    
  